Aurinia Pharmaceuticals (AUPH) Cash from Financing Activities (2018 - 2025)
Historic Cash from Financing Activities for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Q3 2025 value amounting to -$10.5 million.
- Aurinia Pharmaceuticals' Cash from Financing Activities fell 28537.84% to -$10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$127.3 million, marking a year-over-year decrease of 30245.07%. This contributed to the annual value of -$49.1 million for FY2024, which is 85695.91% down from last year.
- According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Cash from Financing Activities is -$10.5 million, which was down 28537.84% from -$44.4 million recorded in Q2 2025.
- Aurinia Pharmaceuticals' 5-year Cash from Financing Activities high stood at $205.7 million for Q4 2021, and its period low was -$49.3 million during Q1 2025.
- In the last 5 years, Aurinia Pharmaceuticals' Cash from Financing Activities had a median value of -$963500.0 in 2022 and averaged $3.6 million.
- Per our database at Business Quant, Aurinia Pharmaceuticals' Cash from Financing Activities skyrocketed by 30469.14% in 2023 and then crashed by 101830.38% in 2024.
- Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Cash from Financing Activities stood at $205.7 million in 2021, then tumbled by 99.67% to $688000.0 in 2022, then tumbled by 910.61% to -$5.6 million in 2023, then crashed by 313.23% to -$23.0 million in 2024, then surged by 54.48% to -$10.5 million in 2025.
- Its Cash from Financing Activities was -$10.5 million in Q3 2025, compared to -$44.4 million in Q2 2025 and -$49.3 million in Q1 2025.